The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
Open accessAbstract
BACKGROUNDS & AIMS The aim of this study is to evaluate the prognostic significances of not only the initial and the best response during repeated transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), but if eligible, also the time point of achieving treatment responses. METHODS Three hundred and fourteen treatment-naïve patients with well-preserved liver function undergoing TACE were recruited. Treatment responses were assessed using modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS) was analyzed using Kaplan-Meier methods, and Cox regression analysis was performed for multivariate analysis. RESULTS After adjusting other variables, objective response (complete response [CR] and partial response [PR]) as the initial response (adjusted hazard ratio [HR] 0.410) and the best response (adjusted HR 0.335) had independent prognostic significances for OS, respectively (both p < 0.001). Objective responders as the initial response had the longest OS, followed by patients who subsequently achieved objective response after at least two sessions and those who did not achieve objective response during treatment course eventually (52.6, 27.0, and 10.8 months, respectively; log-rank test, p < 0.001). Likewise, patients with CR as the initial response had the longest OS, followed by those who subsequently achieved CR after at least two sessions and those who achieved PR as the best response (70.2, 40.6, and 23.0 months, respectively; log-rank test, p < 0.001). Large (>5 cm) and multiple (⩾ 4) tumors were independently associated with failure to achieve CR after the initial TACE (both p < 0.05). CONCLUSION Both the initial and the best response predicts OS effectively. However, achievement of treatment response at an early time point is still the most robust predictor for favorable outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Cited by
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Kudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Self-citationWang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.013 · Cited by 261
Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001834 · Cited by 7
Metadata
- Authors
- Kim, B. K., Kim, S. U., Kim, K. A., Chung, Y. E., Kim, M.-J., Park, M.-S., Park, J. Y., Kim, D. Y., Ahn, S. H., Kim, M. D., Park, S. I., Won, J. Y., Lee, D. Y., & Han, K.-H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 62
- Issue
- 6
- Pages
- 1304-1310
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2025193851
- Cited by
- 202
- References
- 3
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/j.jhep.2015.01.022
- The paper
- Kim, B. K., Kim, S. U., Kim, K. A., Chung, Y. E., Kim, M.-J., Park, M.-S., Park, J. Y., Kim, D. Y., Ahn, S. H., Kim, M. D., Park, S. I., Won, J. Y., Lee, D. Y., & Han, K.-H. (2015). Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2015.01.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.